Biorchestra is developing treatments for neurodegenerative and rare central nervous system diseases. Their proprietary Brain Targeting Drug Delivery System platform technology enables the delivery of nanomedicines, carrying RNA drug cargos, across the blood brain barrier, through a natural transporter, to targeted brain cells. The programs in their pipeline utilize RNA interference technology for their therapeutic strategies. Biorchestra identified the first microRNA linked to neurodegenerative diseases. The company was founded by Dr. Branden Ryu in 2016 with current facilities located in South Korea and Cambridge, Massachusetts.

Biorchestra

Founded: 2016
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin0
Therapy area: Alzheimer&#x27;s
Drug types: NEU, RAR, PED, MUS
Lead product: BMD-001
Funding: $45M D Feb 2022

Drug notes:

About:

Jobs: